Clinical Characterictics and Treatments Modalities of Patients with COVID-19 İnfection During the Early Phase of the Epidemic: A Single-Center from Turkey

Objective: The emergence of coronavirus disease 2019 is a major healthcare threat. We aimed to assist in the management of coronavirus disease 2019 infection and contribute to the literature so the hospitals may find the information about our strategies useful in their efforts to reduce the challenges they are facing in this retrospective single-center study. Methods: We analyzed the data of 1260 laboratory or radiologically confirmed hospitalized cases with coronavirus disease 2019 infection to determine the clinical and epidemiological characteristics. An infectious and a chest disease physician followed all the cases and recorded demographic data, clinical signs, treatment, laboratory, and radiological findings. Results: The mean age of the patients was 51.96 years old, and 665 (52.7%) were male. The most commonly experienced symptoms at the onset of illness were cough, shortness of breath, myalgia, and fever. Most patients showed normal leucocytes counts, lymphopenia, elevated levels of C-reactive protein, procalcitonin, ferritin, lactate dehydrogenase, and creatine kinase. Conclusion: Recognizing the changing treatment modalities is especially important for the management of the coronavirus disease 2019 pandemic.

PDF

___

1. Provenzani A, Polidori P. Covid-19 and drug therapy, what we learned. Int J Clin Pharm. 2020;42(3):833-836. [CrossRef]
2. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J Cancer. 2020;132:199-206. [CrossRef]
3. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Pover. 2020;9(1):29. [CrossRef]
4. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388-393. [CrossRef]
5. Infection guideline for COVID19/SARS COV2 (Turkish ministry of Health-2020). Available at: https://COVID19bilgi.saglik.gov.tr/depo/ rehberler/COVID-19_Rehberi.pdf. Accessed 03.01.2021.
6. Kilic AU, Kara F, Alp E, Doganay M. New threat: 2019 novel coronavirus infection and infection control perspective in Turkey. North Clin Istanb. 2020;7(2):95-98. [CrossRef]
7. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. [CrossRef]
8. Ozma MA, Maroufi P, Khodadadi E, et al. Clinical manifestation, diagnosis, prevention and control of COVID-19 (COVID-19) during the outbreak period. Infez Med. 2020;28(2):153-165.
9. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020;126:108961. [CrossRef]
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [CrossRef]
11. Carotti M, Salaffi F, Sarzi-Puttini P, et al. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. Radiol Med. 2020;125(7):636-646. [CrossRef]
12. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (COVID19). Clin Infect Dis. 2020;71(15):732-739. [CrossRef]
13. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. [CrossRef]
14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. [CrossRef]
15. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446-454. [CrossRef]
16. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI-1):611-619. [CrossRef]
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. [CrossRef]
18. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773. [CrossRef]
19. Ahsan W, Javed S, Bratty MA, Alhazmi HA, Najmi A. Treatment of COVID-19: how far have we reached? Drug Discov Ther. 2020;14(2):67- 72. [CrossRef]
20. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020;6(10):1192-1198. [CrossRef]
21. Naveed M, Uddin S, Abdullah KS, Ishaq SE, Ahmad T. Various evidence-based hypothetical and experimental treatment approaches and their effectiveness against COVID-19 worldwide: a comprehensive literature review. EJMO. 2020;4:265-285. [CrossRef]
22. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. [CrossRef]
23. Lu L, Zhong W, Bian Z, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: a systematic review and meta-analysis. J Infect. 2020;81(4):e18-e25. [CrossRef]
24. Grasselli G, Zangrillo A, Zanella A, et al. COVID-19 Lombardy ICU network. Baseline characteristics and outcomes of 1591 patients infected With COVID-19 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-1581. [CrossRef]
25. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. [CrossRef]
26. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. [CrossRef]
27. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806. [CrossRef]
28. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the seattle region - case series. N Engl J Med. 2020;382(21):2012-2022. [CrossRef]
29. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-430. [CrossRef]
30. Okabayashi T, Kariwa H, Yokota S, et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 2006;78(4):417-424. [CrossRef